1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Urovant’s Vibegron Faces Tough Commercial Climb Despite Phase III Success

 
• By Joseph Haas

Roivant subsidiary thinks EMPOWUR data would position the drug as best-in-class in overactive bladder, but investors responded to the data with a clear thumbs-down.

Petri dish

Urovant Sciences Ltd. believes it has the data in hand to support a 2020 FDA filing for its overactive bladder drug vibegron, with the EMPOWUR trial hitting on all endpoints versus placebo, but underperforming against the generic anticholinergic tolterodine leaves it in a tricky commercial situation – and investors are expressing doubts.

On a March 19 investor call to outline the data, Urovant said vibegron should offer a quicker onset of action than the competing beta 3 adrenergic receptor agonist Myrbetric, with a better safety profile than that drug and the older OAB drugs from anticholinergic (ACH) class

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.